DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
The termination eliminates related share issuance and carries no fees or obligations, while two existing agreements remain in effect.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DataMEDS AI (MEDS) terminated its second amended and restated letter of intent to license or acquire intellectual property for common stock. The company cited market conditions as the reason. The October 19, 2026 agreement involved Datavault AI (DVLT), REBOOT Health AI, EOS Technology Holdings, Scilex Holding Company and HealthBridge Advisors.
DataMEDS owes no fees or obligations from the termination and will issue no shares related to the letter of intent. Its October 13, 2026 exclusive REBOOT license for managing GLP-1 users remains in effect, as does the November 24, 2025 Datavault AI agreement for PharmacyChain manufacturer-to-patient blockchain-enabled smart contracts. No DataMEDS shares were issued to Datavault under that agreement.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.DataMEDS will issue no shares related to the terminated letter of intent, avoiding that dilution.
- Minor pointTermination leaves DataMEDS with no fees or obligations arising from it.
- Minor pointREBOOT's exclusive license for managing GLP-1 users, dated October 13, 2026, remains in effect.
- Minor pointThe Datavault AI PharmacyChain agreement remains in effect; no DataMEDS shares were issued under it.
Negative
- Moderate pointTermination ends the proposed intellectual-property licensing or acquisition transaction; DataMEDS cited market conditions.
Previous AI Reports
-
DataMEDS amended the LOI for healthcare technology licensing and IP acquisition, with closing expected in fourth-quarter 2026.
-
DataMEDS signed an exclusive REBOOT platform license, the agreement it confirms remains in force.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has terminated the Second Amended and Restated letter of intent dated October 19, 2026 ("2nd LOI") with Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.'s ("DHP") wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. ("EOS"), Scilex Holding Company ("Scilex") and HealthBridge Advisors, LLC ("HealthBridge Advisors") for the in-license or acquisition of IP in exchange for Company common stock due to market conditions. DataMEDS does not owe any fees or obligation as a result of the termination.
As a result of the termination of the 2nd LOI, DataMEDS will no longer be issuing any shares related to the 2nd LOI.
DataMEDS confirms that its exclusive license with REBOOT for the management of GLP-1 users, dated October 13, 2026, remains in full force and effect.
Datavault AI for PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts remains in full force and effect, in accordance with the terms of that agreement dated November 24, 2025. No shares of the Company were issued to Datavault in connection with that agreement.
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: the effects of the cancellation of the LOI on the Company's business, strategy and technology plans; the Company's ability to identify, negotiate and complete alternative acquisitions, licenses or partnerships on acceptable terms or at all; any costs, claims or disputes that may arise in connection with the LOI or its cancellation; the status of any other existing agreements or relationships with the parties to the LOI; the Company's capitalization and any future issuances of its securities; the Company's ability to execute its existing business plans, including those of Health Lives Here, Corexa Health and Helomics; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
###
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did DataMEDS AI terminate its second amended letter of intent?
DataMEDS cited market conditions for terminating the October 19, 2026 letter of intent. It covered licensing or acquiring intellectual property in exchange for DataMEDS common stock.